NCT05795244View on ClinicalTrials.gov

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Endometrial NeoplasmsEndometrial Cancer
Interventions
DRUG

Nivolumab

\- Nivolumab 480 mg/every 4 weeks/IV infusion/6 cycles

Trial Locations (1)

Unknown

RECRUITING

Severance Hospital, Yonsei University Health System, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER